
Our multidisciplinary team of experts is committed to providing the highest level of diagnostic accuracy and patient care. This is done using the latest neurophysiological tests, MRI scans, nerve and muscle techniques. Our scientific interests range from basic research, such as novel drug development or studies using disease models of ALS, to clinical studies (e.g clinical trials, MRI studies). We are part of the Institute of Experimental Neurology (INSPE), which is dedicated to translational research in the neuroscience field, and we collaborate with several laboratories in Italy and Europe.
Contact
LocationOspedale San Raffaele, Via Olgettina Milano, Milan, Metropolitan City of Milan, Italy
Contact
Current trials
Recruiting
Phase iii
ATLAS trial
Industry trial
Biogen is conducting a clinical trial to evaluate the efficacy and safety and of an investigational drug for adults who do not have any clinical signs or symptoms of Amyotrophic Lateral Sclerosis (ALS) (that definitely indicate the onset of ALS) but do carry a certain superoxide dismutase 1 (SOD1) gene variant.
Recruiting
Phase iii
FUSION trial
Industry trial
In this study we investigate the safety and efficacy of the study drug ‘ION363’ for the treatment of ALS caused by mutations in the FUS gene. About 1% to 5% of ALS cases are caused by FUS mutations.
Active
Phase iii
PHOENIX trial
Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Active
Phase iii
ADORE trial
Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Active
Phase iii
TUDCA-ALS
Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.